AMARIN CORP PLC -ADR (AMRN) Stock News

NASDAQ:AMRN - Nasdaq - US0231114044 - ADR - Currency: USD

15.65 +0.61 (+4.06%)

After market: 15.66 +0.01 (+0.06%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AMRN Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Zacks Investment Research - Mentions: ALLO AKRO ALGS

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

3 days ago - By: Zacks Investment Research

Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

18 days ago - By: Amarin Corporation plc

Amarin Reports Second Quarter 2025 Financial Results

18 days ago - By: Amarin Corporation plc

Amarin Reports Second Quarter 2025 Financial Results

18 days ago - By: Benzinga - Mentions: ALL ZIMV NEU LRCX ...

Earnings Scheduled For July 30, 2025

25 days ago - By: Amarin Corporation plc

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

25 days ago - By: Amarin Corporation plc

Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025

2 months ago - By: Benzinga

Amarin Shares Surge After $175M European Licensing Deal For Heart Drug VAZKEPA

2 months ago - By: Amarin Corporation plc

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

2 months ago - By: Amarin Corporation plc

Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe

2 months ago - By: Zacks Investment Research - Mentions: REGN SNY EXEL

Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid

2 months ago - By: Zacks Investment Research - Mentions: LXRX KURA CMMB

KURA Stock Rises More Than 15% This Past Week: Here's Why

2 months ago - By: Zacks Investment Research - Mentions: LXRX ZTS

Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio?

2 months ago - By: Zacks Investment Research - Mentions: LXRX LYRA

Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success

2 months ago - By: Zacks Investment Research - Mentions: JNJ LXRX

JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer

3 months ago - By: Zacks Investment Research - Mentions: SNY BPMC

Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines

3 months ago - By: Zacks Investment Research - Mentions: LXRX IMVT

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus

3 months ago - By: Zacks Investment Research - Mentions: JNJ ORIC

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

3 months ago - By: Zacks Investment Research - Mentions: BMY LXRX

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

3 months ago - By: Zacks Investment Research - Mentions: LXRX CMMB CADL

CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

3 months ago - By: Zacks Investment Research - Mentions: GSK

Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?

3 months ago - By: Yahoo Finance - Mentions: NVDA TTEK ATMU COMP ...

Wall Street ends up with Nvidia, appeals court reinstates Trump tariffs

3 months ago - By: Zacks Investment Research - Mentions: LXRX RCKT CMMB

RCKT Stock Tanks on Patient Death in Danon Disease Study

3 months ago - By: Zacks Investment Research - Mentions: TEVA LXRX CMMB

TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate

3 months ago - By: Zacks Investment Research - Mentions: LXRX VSTM

VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval

3 months ago - By: Zacks Investment Research - Mentions: AZN HALO LXRX

AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer

3 months ago - By: Zacks Investment Research - Mentions: GSK HALO LXRX

GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma

3 months ago - By: Zacks Investment Research - Mentions: HALO LXRX SWTX

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

3 months ago - By: Zacks Investment Research - Mentions: REGN HALO

Bayer Gets CHMP Nod for Eylea 8 mg in the EU for 2 Major Eye Diseases

3 months ago - By: Zacks Investment Research - Mentions: BMY EXEL

EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort

3 months ago - By: Zacks Investment Research - Mentions: HALO BBIO

Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation

3 months ago - By: Zacks Investment Research - Mentions: HALO ARMP

ARMP Soars 72% in a Month Following Infectious Disease Study Success

3 months ago - By: Zacks Investment Research - Mentions: SIRI VRTX HALO CRSP

CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies

3 months ago - By: Zacks Investment Research - Mentions: BEAM ANIP NTLA

Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

3 months ago - By: Amarin Corporation plc

Amarin Reports First Quarter 2025 Financial Results

3 months ago - By: Amarin Corporation plc

Amarin Reports First Quarter 2025 Financial Results